Drug Trial Radar · NCT06704828
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 2024
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4602 as montherapy or in combination with other anti-tumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-4602 for advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-4602Drug
SHR-4602
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR by investigator assessmentTime frame: Up to approximately 5 years;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.